The classification of lymphomas and leukemias
The classification of lymphomas and leukemias
Classifications of lymphomas and leukemias have developed from two distinct clinical needs — to understand the natural history of these diseases in order to predict outcome and to make treatment decisions in a rational fashion. The utility of classifications for research on etiology of these diseases has not guided their development in the past. The classification of leukemias and lymphomas has undergone dramatic changes with increasing understanding of the development of the normal immune cells. Historically, the first entity to be recognised was Hodgkin disease. Other malignancies of the lymphatic system were then called ‘Non-Hodgkin Lymphomas’ (NHL), a distinction that remains valid even today. Cancers that tend not to form distinct masses but usually present with a raised white blood cell count were called leukemias. As knowledge has improved, however, the early juxtaposition of leukemias versus lymphomas has lost relevance, since often the same entity can present in either way. With better understanding the terms ‘lymphosarcoma’ and ‘reticulosarcoma’, which were earlier widely applied have been replaced by more precise terminology. Different classifications have been put forward over the years. The ‘Revised European and American Classification of Lymphoid Neoplasms’ and the derived WHO classification are structured to mirror normal B/T-cell differentiation. In these modern classifications, distinct disease entities are defined based on the combination of morphology, immunological and molecular techniques and clinical features. The proposed major groups of lymphoid neoplasms are B-cell lymphomas/leukemias, T/Natural Killer-cell lymphomas/leukemias and Hodgkin disease. About 20 entities are recognised. This provides for the first time a truly international view of lymphomas and leukemias. It has emerged that such a classification can be used successfully by expert hematopathologists and yields highly reproducible results. It is also clear that no single marker, be it morphology, genetic analysis or immunophenotyping can be used as the ‘gold standard’ for diagnosis but that a combination of techniques is needed.
leukemia, lymphoma, Hodgkin disease, Hodgkin lymphoma, leukemia/*classification, lymphoma/*classification, B-cell/classification, World Health Organization
653-664
Ottensmeier, Christian
42b8a398-baac-4843-a3d6-056225675797
2001
Ottensmeier, Christian
42b8a398-baac-4843-a3d6-056225675797
Abstract
Classifications of lymphomas and leukemias have developed from two distinct clinical needs — to understand the natural history of these diseases in order to predict outcome and to make treatment decisions in a rational fashion. The utility of classifications for research on etiology of these diseases has not guided their development in the past. The classification of leukemias and lymphomas has undergone dramatic changes with increasing understanding of the development of the normal immune cells. Historically, the first entity to be recognised was Hodgkin disease. Other malignancies of the lymphatic system were then called ‘Non-Hodgkin Lymphomas’ (NHL), a distinction that remains valid even today. Cancers that tend not to form distinct masses but usually present with a raised white blood cell count were called leukemias. As knowledge has improved, however, the early juxtaposition of leukemias versus lymphomas has lost relevance, since often the same entity can present in either way. With better understanding the terms ‘lymphosarcoma’ and ‘reticulosarcoma’, which were earlier widely applied have been replaced by more precise terminology. Different classifications have been put forward over the years. The ‘Revised European and American Classification of Lymphoid Neoplasms’ and the derived WHO classification are structured to mirror normal B/T-cell differentiation. In these modern classifications, distinct disease entities are defined based on the combination of morphology, immunological and molecular techniques and clinical features. The proposed major groups of lymphoid neoplasms are B-cell lymphomas/leukemias, T/Natural Killer-cell lymphomas/leukemias and Hodgkin disease. About 20 entities are recognised. This provides for the first time a truly international view of lymphomas and leukemias. It has emerged that such a classification can be used successfully by expert hematopathologists and yields highly reproducible results. It is also clear that no single marker, be it morphology, genetic analysis or immunophenotyping can be used as the ‘gold standard’ for diagnosis but that a combination of techniques is needed.
This record has no associated files available for download.
More information
Published date: 2001
Keywords:
leukemia, lymphoma, Hodgkin disease, Hodgkin lymphoma, leukemia/*classification, lymphoma/*classification, B-cell/classification, World Health Organization
Identifiers
Local EPrints ID: 26507
URI: http://eprints.soton.ac.uk/id/eprint/26507
ISSN: 0009-2797
PURE UUID: ce29410b-a66f-44cd-8c48-36c9507a9c00
Catalogue record
Date deposited: 24 Apr 2006
Last modified: 15 Mar 2024 07:11
Export record
Altmetrics
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics